Exclusion criteria
cardio-embolic, bleeding, calcification, seizures, epilepsy, stroke, allergy, patent foramen ovale, neurological deficit, organ failure, cardioembolic ischemic stroke, meningioma, acute myocardial infarction, head trauma, active peptic ulcers, hypotension, venous thrombosis, embolus, ischemic stroke, atrial fibrillation
ACUTE MYOCARDIAL INFARCTION, BLEEDING, EPILEPSY, STROKE, MINOR, ALLERGY, CARDIAC ARREST, ISCHEMIC STROKE, AORTIC VALVE STENOSIS, SECONDARY, MALIGNANCIES, MULTIPLE SCLEROSIS, MITRAL VALVE PROLAPSE, ATRIAL FIBRILLATION, PATHOLOGY, MENINGIOMA, VENOUS THROMBOSIS
We excluded patients who had not been followed up on for 90 days after enrollment, those with NIHSS less than three or more than 25 or who had rapidly resolving symptoms before imaging results, patients with a known history of persistent or recurrent CNS pathology (e.g., epilepsy, meningioma, multiple sclerosis, history of head trauma with a residual neurological deficit).We excluded patients who had a cardioembolic ischemic stroke before starting treatment or retrogradely. We considered ischemic stroke a cardio-embolic one when the patient had major or minor risk factors of having a cardiac source of embolus as mechanical cardiac valves, atrial fibrillation, mitral valve prolapse, aortic valve stenosis or calcification, and patent foramen ovale [We ruled out patients who had already recurrent stroke before enrollment in our trial diagnosed by appropriate clinical history and/or MRI brain findings, as those patients might receive antiplatelet treatment as secondary prevention and might have a residual neurological deficit which could bias the assessment of safety and efficacy of the antiplatelet in our trial.We excluded patients who had clinical seizures at the onset of their stroke, as well as those who had symptoms of any major organ failure, active malignancies, or an acute myocardial infarction within the previous 6 weeks, and those who were on warfarin or new oral anticoagulants, regular ticagrelor during the week before admission, or chemotherapy within the previous year.For safety measures and to avoid associated confounders, we excluded patients with active peptic ulcers, GIT surgery, bleeding history within the last year, and those with a history of major surgery within the last 3 months.We ruled out of our trial patients who had a known allergy to the study drugs and those with INR > 1.4, P.T. > 18, blood glucose level < 50, > 400 mg/DL, blood pressure < 90/60, > 185/110 mmHg on admission, or platelets < 100,000.We considered pregnant and lactating patients or those with stroke due to venous thrombosis and stroke following cardiac arrest, or profuse hypotension ineligible for our trial.